Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | HRH2 | P25021 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696667 | 0.85 | MAPK1 (0.36) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4696318 | 0.85 | MAPK1 (0.36) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4696998 | 0.82 | MAPK1 (0.35) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4696453 | 0.82 | MAPK1 (0.35) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4694428 | 0.79 | MAPK1 (0.33) | F11MAPK1HRH4DRD2DRD4 | |
| SCHEMBL4694084 | 0.79 | MAPK1 (0.33) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4693179 | 0.79 | MAPK1 (0.33) | F11MAPK1NPC1HRH4DRD2 | |
| SCHEMBL4695749 | 0.77 | MAPK1 (0.32) | MAPK1CHRM2HTR1AADRA2ADRD1 | |
| SCHEMBL4692968 | 0.77 | MAPK1 (0.32) | MAPK1CHRM2HTR1AADRA2ADRD1 | |
| SCHEMBL5225145 | 0.77 | MAPK1 (0.37) | F11MAPK1NPC1HRH4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | F11 2597/4885MAPK1 2268/4885NPC1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.